Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy – Business Wire October 30, 2023
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an – GlobeNewswire October 10, 2023
Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder – MarketWatch August 7, 2023
AstraZeneca dives into regulatory T cell therapies in deal with Quell Therapeutics – Endpoints News June 9, 2023
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc. – Yahoo Finance February 13, 2023
Frequency Therapeutics reports trial fail and lays off over half of staff — stock capsizes – Endpoints News February 13, 2023
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss – Yahoo Finance February 13, 2023
G1 Therapeutics abandons PhIII colorectal cancer trial after disappointing overall response rates – Endpoints News February 13, 2023
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) – Yahoo Finance February 13, 2023